Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
IS THE NEWS OUT? Data from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and ICM administration achieved comparable biodistribution across brain and spinal cord regions in NHPs Findings from the analysis reaffirm the clinical potential of IT administration as an effective, safe and minimally invasive approach to deliver AAV-based gene therapies designed to treat CNS diseases in both children and adults “Findings from an analysis across five NHP studies showed that both IT and ICM administration led to comparable, consistent and widespread biodistribution of AAV9 vector throughout the brain and spinal cord regions,” said Sukumar Nagendran, M.D., President and Head of Research & Development at Taysha. “Importantly, these findings further support the clinical potential of IT administration as an effective, safe and minimally invasive delivery approach for broad targeting of the CNS that has potential for outpatient use in both children and adults. We believe the NHP biodistribution data, together with our additional preclinical data, reaffirm our clinical development strategy utilizing IT administration and provide translational support for the broad clinical effect reported following treatment with TSHA-102 in both our REVEAL adolescent/adult trial and REVEAL pediatric trial."
YOU MAY OF NOTICED WE LET GO SOME OF OUR CONSUMER PLAYS YESTERDAY. mainly the burger ones! WEN is a beautiful total return idea from GBA but the chart spells trouble now. I don't see it going down but i don't see it going up. Red Robin was a typical GBA home run in the dining sector like so many before! The children are blessed. Sweet Green we have at a large gain still and that's about it, we have let go Wingstop and CAVA and BROS. In general with the violence to come after the election results, when Trump tries to claim victory even though he loses.. this is probably not a good time to go out and eat. I'm watching WMT because it worked great for us and I would be interested in the name in a retrace. Also watching BOOT. But in general it's a hunker down sort of time.
Watch-->TSHA Taysha Gene Therapies, Inc.@ $2.00 Watch--> HONHoneywell International Inc.@ $ 220 HON Update- Pick UP HON here- HON Honeywell International Inc. Stock Price & Overview $194.21-0.58 (-0.30%)10:02 AM 04/25/24 #16753 Apr 25, 2024 Report Reply Share Finally getting traction. This was a great call and write up-- Not Your father's Honeywell... Search for it> HON Honeywell International Inc. $217.38 0.41(+0.19%)4:00 PM 07/23/24 #60 Jul 24, 2024 Report Reply Share There is no way to sugar coat it: HON has been a pain in the ass a bunch of false break outs. Is now the time?
I believe SOUN will jump to $8 on their earn report. I have no reason to believe this other than I notice some attention suddenly being paid to the name at yahoo finance. They have two pieces that aren't headlined SOUN but talk about SOUN. One is an article about NVDA's own investments-- SOUN is in there- and one was another article IBD about stocks to buy and SOUN was one of four. Still it's nice to see the name popping up and I wonder if it's in anticipation of abig move. My favorite long shot SOUN. SOUN SoundHound AI, Inc. T- $7.45 $5.34-0.05(-0.93%)9:47 AM 10/22/24 NASDAQ |$USD |Realtime
From Aug 12. This is a reduction in PT not a good thing! But it gives valuable timing info.- Analyst Gil Blum of Needham maintained a Buy rating on Taysha Gene Therapies (TSHA–Research Report), reducing the price target to $6.00. Gil Blum has given his Buy rating due to a combination of factors that suggest a positive outlook for Taysha Gene Therapies. The anticipated high-dose results for TSHA-102, which are now expected in the first half of 2025, are set to include data from six patients, both pediatric and adult, with at least six months of follow-up. This delayed timing for the readout is strategic, allowing for a more comprehensive disclosure of longer-term results from the low-dose cohorts as well. The firm’s proactive planning for an end of Phase I meeting with the FDA to discuss pivotal study design for TSHA-102, leveraging its RMAT status, also underpins the rating. Furthermore, Blum sees potential in the upcoming initial efficacy results for Neurogene’s NGN-401, expected in the fourth quarter of 2024, which could serve as another near-term catalyst for the company. The financial stability is another key factor, with Taysha ending the second quarter of 2024 with a significant cash reserve of $173 million. Although the target price has been adjusted to $6, the decision to delay the readout is viewed as a logical step in ensuring a more robust set of data, which justifies maintaining the Buy rating for Taysha Gene Therapies. GBA Note* -> Short Interest 10.07%